...
首页> 外文期刊>American Journal of Pathology: Official Publication of the American Association of Pathologists >The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells.
【24h】

The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells.

机译:内皮的半乳凝素谱:在活化和肿瘤内皮细胞中表达和定位的改变。

获取原文
获取原文并翻译 | 示例
           

摘要

We previously identified overexpression of galectin-1 in activated tumor endothelium. Currently, the tumor vasculature is a target for therapeutic approaches. Little is known about galectin expression and regulation in the tumor vasculature. Here, we report the expression of galectin-1/-3/-8/-9 in the endothelium as determined by quantitative PCR, Western blot, flow cytometry, and immunohistochemistry. Galectin-2/-4/-12 were detectable at the mRNA level, albeit very low. Galectin-8 and -9 displayed alternative splicing. Immunohistochemistry of normal tissues revealed a broad but low expression of galectin-1 in the vasculature, whereas the expression levels and localization of the other galectins varied. Endothelial cell activation in vitro significantly increased the expression of galectin-1 (5.32 +/- 1.97; P = 0.04) and decreased the expression of both galectin-8 (0.59 +/- 0.12; P < 0.04) and galectin-9 (0.32 +/- 0.06; P < 0.002). Galectin-3 expression was unaltered. Although a portion of these proteins is expressed intracellularly, the membrane protein level of galectin-1/-8/-9 was significantly increased on cell activation in vitro, 6-fold (P = 0.005), 3-fold (P = 0.002), and 1.4-fold (P = 0.04), respectively. Altered expression levels and cellular localization was also observed in vivo in the endothelium of human tumor tissue compared with normal tissue. These data show that endothelial cells express several members of the galectin family and that their expression and distribution changes on cell activation, resulting in a different profile in the tumor vasculature. This offers opportunities to develop therapeutic strategies that are independent of tumor type.
机译:我们先前发现在激活的肿瘤内皮细胞中galectin-1的过表达。当前,肿瘤脉管系统是治疗方法的目标。关于半乳凝素在肿瘤脉管系统中的表达和调控知之甚少。在这里,我们报道了通过定量PCR,Western印迹,流式细胞仪和免疫组化测定的半乳糖凝集素-1 / -3 / -8 / -9在内皮中的表达。在mRNA水平上可以检测到Galectin-2 / -4 / -12,尽管非常低。 Galectin-8和-9显示了替代剪接。正常组织的免疫组织化学分析显示,galectin-1在脉管系统中表达广泛但较低,而其他galectin的表达水平和定位则有所不同。体外内皮细胞活化显着增加galectin-1(5.32 +/- 1.97; P = 0.04)的表达并降低galectin-8(0.59 +/- 0.12; P <0.04)和galectin-9(0.32)的表达+/- 0.06; P <0.002)。 Galectin-3的表达未改变。尽管这些蛋白的一部分在细胞内表达,但半乳糖凝集素-1 / -8 / -9的膜蛋白水平在体外细胞激活后显着增加,分别为6倍(P = 0.005),3倍(P = 0.002)。 ,和1.4倍(P = 0.04)。与正常组织相比,在人肿瘤组织的内皮中还观察到体内表达水平和细胞定位的改变。这些数据表明内皮细胞表达半乳凝素家族的几个成员,并且它们的表达和分布在细胞激活时发生变化,从而导致肿瘤脉管系统的轮廓有所不同。这提供了发展与肿瘤类型无关的治疗策略的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号